1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Reviva’s First Phase III Schizophrenia Readout Rivals Karuna’s Stellar KarXT

Biotech Will Need Cash To Finalize Pivotal Program

 
• By Mandy Jackson

Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.

Schizophrenia and split personality disorder and mental health psychiatric disease concept
Reviva plans to also develop its drug for bipolar disorder, depression and ADHD • Source: Shutterstock

Reviva Pharmaceuticals Holdings, Inc. saw its stock price jump nearly 50% on 30 October after the small-cap company reported that brilaroxazine succeeded in its first Phase III clinical trial in schizophrenia with results that look just as good and potentially slightly better than data for KarXT, which caused Karuna Therapeutics, Inc.’s valuation to double last year.

Key Takeaways

  • Reviva reported positive results from the first Phase III trial of its selective serotonin and dopamine modulator brilaroxazine in schizophrenia.

KarXT has become one of the most closely watched new drugs in neuropsychiatry after the company delivered results from the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.